Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Open Access
- 26 October 2007
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 9 (5), R74
- https://doi.org/10.1186/bcr1783
Abstract
At the time when metastatic disease is identified, assessment of human epidermal growth factor receptor (HER)2 status might help to optimize treatment decisions if HER2 status was not determined at first diagnosis and if HER2 positivity has been acquired during disease progression. Within this context, determination of serum HER2 or evaluation of HER2 status in circulating tumor cells (CTCs) may be of clinical relevance because metastatic tissue may be difficult to obtain for analysis as a result of its localization. The aim of this study was therefore to determine the HER2 status in serum and corresponding CTCs in patients with metastatic breast cancer whose primary tumors were HER2 negative or of unknown HER2 status.Keywords
This publication has 44 references indexed in Scilit:
- Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trialsBMC Cancer, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- uPAR and HER-2 gene status in individual breast cancer cells from blood and tissuesProceedings of the National Academy of Sciences of the United States of America, 2006
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall SurvivalClinical Cancer Research, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Change of HER‐2/neu status in a subset of distant metastases from breast carcinomasThe Journal of Pathology, 2004
- HER-2 gene amplification can be acquired as breast cancer progressesProceedings of the National Academy of Sciences of the United States of America, 2004
- Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast CancerClinical Cancer Research, 2004
- HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast CancerJournal of Clinical Oncology, 2003